liver signal profiling and blood marker research for non-alcoholic fatty liver diseases
Not Applicable
Recruiting
- Conditions
- nonalcoholic fatty liver diseases
- Registration Number
- JPRN-UMIN000013323
- Lead Sponsor
- Saga Medical School Hiroshima University Yokohama City University Graduate School of Medicine Takeda Pharmaceutical Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Persons over 20g per day or 140g per week of alcohol intake 2) Patients who are suspicious of viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, alpha1-antitrypsin deficiency, Wilson's disease, drug-induced hepatitis 3) Patients who showed clinical evidence of hepatic decompensation such as hepatic encephalopathy, ascites, variceal bleeding, or a serum bilirubin level greater than twofold the normal upper limit 4) Persons judged inappropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Proceeding Genechip analysis, Methylation BeadChip analysis, and comprehensive analysis of miRNA for signal profiling in liver by using liver biopsy samples collected in each trial sites 2) Proceeding Proteomics analysis, metabolomics analysis, and comprehensive analysis of miRNA to research diagnostic markers for NASH by using blood samples collected in each trial sites
- Secondary Outcome Measures
Name Time Method